N-(4-乙酰苯基)-2-苯基-乙酰胺 | 89246-39-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N-(4-乙酰苯基)-2-苯基-乙酰胺
• 英文名称: N-(4-acetylphenyl)-2-phenylacetamide
• CAS: 89246-39-9
• 化学式: C₁₆H₁₅NO₂
• mdl: MFCD00431008
• 分子量: 253.301
• InChiKey: NSAFMUGXEWLJDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  121-123 °C(Solv: ethanol (64-17-5))
• 沸点：
  493.7±38.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N-(4-乙酰苯基)-2-苯基-乙酰胺 在 溶剂黄146 、 三氟乙酸 、 sodium hydroxide 作用下， 反应 24.0h， 生成
  参考文献：
  名称：

  嘧啶-2-醇新型二级药效团酰胺基可溶性环氧化物水解酶抑制剂的合成、对接研究及生物学评价

  摘要：

  可溶性环氧化物水解酶 (sEH) 是开发针对多种疾病适应症（包括高血压、糖尿病、中风、血脂异常、疼痛等）的药物的最有希望和新兴的靶标之一。大多数抑制剂支架具有尿素或酰胺部分以模拟活性-位点转换状态。对此，我们开发了一系列以嘧啶-2-醇环作为新的二级药效团的酰胺sEH抑制剂，并进行了体外评价。化合物4w (4 -chloro- N- {4-[6-(4-chlorophenyl)-2-hydroxypyrimidin-4-yl]phenyl}benzamide)，在两个末端苯环中都含有 4-chloro 取代基，表现出最强的抑制作用具有 IC 50的抗 sEH 活性值为 1.2 nM。合成化合物的分子对接分析表明，作为主要药效团的酰胺基团与作为酶的关键催化残基三联体的 Asp-353、Tyr-383 和 Tyr-466 之间存在更多的氢键相互作用，起到了关键作用并导致更有利的结合亲和力。在计算

  DOI：

  10.1002/cbdv.202200231
• 作为产物：
  描述：

  4-氨基苯乙酮 、 苯乙酰氯 生成 N-(4-乙酰苯基)-2-苯基-乙酰胺
  参考文献：
  名称：

  Electronic properties of anticonvulsant amides. A C-13 nuclear magnetic resonance study of phenylacetanilides.

  摘要：

  制备了约20种苯胺环上带有对位和间位取代基的苯乙酰苯胺，并测量了它们的C-13核磁共振谱。通过双取代基参数 (DSP) 和 DSP-非线性共振 (DSP-NLR) 方程检查对碳原子的取代基化学位移 (SCS)。通过 DSP 分析获得了极好的相关性。结果表明-NHCOCH2Ph部分是弱电子供体。化学位移数据和推导的相关性与取代的丙酰苯胺获得的数据非常相似。

  DOI：

  10.1248/cpb.31.4172

文献信息

• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20080039449A1

  公开（公告）日：2008-02-14

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing-N-acylamino compounds.

  本发明涉及一种新型的化合物类别，其为白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以作为抗IL-1、凋亡、IGIF、IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、感染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用这些化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、降低IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME
  申请人：Batchelor Mark James

  公开号：US20110178069A1

  公开（公告）日：2011-07-21

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一种新型化合物类别，其为白细胞介素-1β转化酶抑制剂。本发明的ICE抑制剂具有特定的结构和物理化学特征。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制ICE活性，因此可以优势地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及使用本发明的化合物和组合物抑制ICE活性、治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病、减少IGIF和IFN-γ产生的方法。本发明还涉及制备N-酰基氨基化合物的方法。
• Design and synthesis of new indole drug candidates to treat Alzheimer’s disease and targeting neuro-inflammation using a multi-target-directed ligand (MTDL) strategy
  作者：Phoebe F. Lamie、Maha M. Abdel-Fattah、John N. Philoppes

  DOI：10.1080/14756366.2022.2126464

  日期：2022.12.31

  Abstract A novel series of indole-based compounds was designed, synthesised, and evaluated as anti-Alzheimer’s and anti-neuroinflammatory agents. The designed compounds were in vitro evaluated for their AChE and BuChE inhibitory activities. The obtained results revealed that compound 3c had higher selectivity for AChE than BuChE, while, 4a, 4b, and 4d showed selectivity for BuChE over AChE. Compounds

  摘要 一系列基于吲哚的新型化合物被设计、合成和评估为抗阿尔茨海默病和抗神经炎症剂。对设计的化合物进行体外评估其 AChE 和 BuChE 抑制活性。所得结果表明，化合物3c对AChE的选择性高于BuChE，而4a、4b和4d对BuChE的选择性高于AChE。化合物5b、6b、7c和10b在纳摩尔范围内发挥双重 AChE/BuChE 抑制活性。化合物5b和6b具有抑制自身诱导的Aβ淀粉样蛋白聚集的能力。评估了化合物5b和6b的不同抗炎介质（NO、COX-2、IL-1β 和 TNF-α）。在体外筛选了5b和6b对人神经母细胞瘤 (SH-SY5Y) 和正常肝 (THLE2) 细胞系的细胞毒作用。进行了rh AChE和h BuChE活性位点内的分子对接研究、药物相似性和ADMET预测。
• Inhibitors of interleukin-1ß converting enzyme
  申请人：Vertex Pharmceuticals Incorporated

  公开号：EP2083014A2

  公开（公告）日：2009-07-29

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physiochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases and decreasing IGIF, and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，它们是白细胞介素-1β转换酶的抑制剂。本发明的 ICE 抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 ICE 的活性，因此可作为抗 IL-1、细胞凋亡、IGIF 和 IFN-γ 介导的疾病、炎症性疾病、自身免疫性疾病、破坏性骨疾病、增殖性疾病、感染性疾病、退行性疾病和坏死性疾病的药物。本发明还涉及使用本发明化合物和组合物抑制 ICE 活性、治疗白细胞介素-1、细胞凋亡、IGIF 和 IFN-γ 介导的疾病以及减少 IGIF 和 IFN-γ 生成的方法。本发明还涉及制备 N-酰氨基化合物的方法。
• Structure-based modification of 3-/4-aminoacetophenones giving a profound change of activity on tyrosinase: From potent activators to highly efficient inhibitors
  作者：Ao You、Jie Zhou、Senchuan Song、Guoxun Zhu、Huacan Song、Wei Yi

  DOI：10.1016/j.ejmech.2015.02.013

  日期：2015.3

  In this study, we developed 3-/4-aminoacetophenones and their structure-based 3-/4-aminophenylethylidenethiosemicarbazide derivatives, respectively, as novel tyrosinase activators and inhibitors. Notably, all the obtained thiosemicarbazones displayed more potent tyrosinase inhibitory activities than kojic acid. Especially, compound 7k was found to be the most active tyrosinase inhibitor with IC50 value of 0.291 mu M. The structure-activity relationships (SARs) analysis showed that: (1) the amine group was absolutely necessarily for determining the tyrosinase activation activity; (2) the introduction of thiosemicarbazide group played a very vital role in transforming tyrosinase activators into tyrosinase inhibitors; (3) the phenylethylenethiosemicarbazide moiety was crucial for determining the tyrosinase inhibitory activity; (4) the type of acyl group had no obvious effect on the inhibitory activity; (5) the position of amide substituent on the phenyl ring influenced the tyrosinase inhibitory potency. Moreover, the inhibition mechanism and inhibition kinetics study revealed that compound 7k was reversible and non-competitive inhibitor, and compound 8h was reversible and competitive-uncompetitive mixed-II type inhibitor. (C) 2015 Elsevier Masson SAS. All rights reserved.